Concomitant radiochemotherapy in rectal cancer: methodology and indications

Area of Science:

• Oncology
• Radiation Oncology
• Medical Oncology

Background:

• Concomitant chemoradiotherapy (CRC) combines chemotherapy and radiation therapy (ERT) for synergistic effects.
• 5-fluorouracil (5FU) is a key chemotherapeutic agent used in CRC for rectal cancer treatment.
• The study analyzes the role of ERT enhancement in rectal cancer therapy.

Purpose of the Study:

• To analyze the role of enhanced radiation therapy (ERT) in rectal cancer treatment.
• To evaluate the efficacy and toxicity of concomitant radiochemotherapy (CRC) with 5FU.
• To compare different administration methods of 5FU in CRC.

Main Methods:

• Review of clinical and experimental evidence on CRC with 5FU for rectal cancer.
• Analysis of randomized CRC studies comparing different treatment arms (surgery, ERT, bolus CRC).
• Evaluation of outcomes in patients with resectable and unresectable rectal lesions.

Main Results:

• Continuous infusion 5FU after radiation enhances ERT, yielding mild toxicity.
• Bolus 5FU administration shows additivity with ERT, but improved local control and survival at higher toxicity.
• CRC demonstrates high local control (85-90%) and 5-year survival (55-60%) in resectable lesions compared to controls.
• For unresectable lesions, CRC achieves high surgical radicality (85-90%), complete pathologic response (4-20%), and favorable survival (70-90%).
• Bolus 5FU combinations result in higher Grade 3-4 gastrointestinal toxicity.

Conclusions:

• Continuous infusion 5FU post-radiation is a preferred method for enhancing ERT in rectal cancer due to efficacy and tolerability.
• CRC offers significant improvements in local control and survival for both resectable and unresectable rectal cancers.
• Careful consideration of 5FU administration method is crucial to balance efficacy and toxicity.